Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Directly Reprogramming Nerve Cells in the Brain

By BiotechDaily International staff writers
Posted on 04 Apr 2013
Image: Reprogrammed nerve cell (Photo courtesy of Malin Parmar).
Image: Reprogrammed nerve cell (Photo courtesy of Malin Parmar).
Generating new cells in the body to cure disease, the purview of cell therapy, has taken another significant step in the development toward new treatments. New Swedish research demonstrated that it is possible to reprogram other cells to become nerve cells, directly in the brain.

Two years ago, researchers in Lund University (Sweden) were the first in the world to reprogram fibroblasts to dopamine-producing nerve cells, without going through the stem cell stage. The scientists are now going further and shown that it is possible to reprogram both skin cells and support cells directly to nerve cells, in place in the brain.

“The findings are the first important evidence that it is possible to reprogram other cells to become nerve cells inside the brain,” said Dr. Malin Parmar, research group leader and reader in neurobiology at Lund.

The researchers employed genes designed to be switched on or off using a drug. The genes were inserted into two types of human cells, glia cells and fibroblasts, support cells that are naturally present in the brain. Once the researchers had transplanted the cells into the brains of rats, the genes were triggered using a drug in the animals’ drinking water. The cells then began their conversion into nerve cells.

In other research with lab mice, where similar genes were injected into the mice’s brains, the investigators also were able to reprogram the mice’s own glia cells to become nerve cells. “The research findings have the potential to open the way for alternatives to cell transplants in the future, which would remove previous obstacles to research, such as the difficulty of getting the brain to accept foreign cells, and the risk of tumor development,” said Dr. Parmar.

The new technique of direct reprogramming in the brain could create new ways to more successfully replace dying brain cells in disorders such as Parkinson’s disease. “We are now developing the technique so that it can be used to create new nerve cells that replace the function of damaged cells. Being able to carry out the reprogramming in vivo makes it possible to imagine a future in which we form new cells directly in the human brain, without taking a detour via cell cultures and transplants,” concluded Dr. Parmar.

The study’s findings were published March 26, 2012, in the journal Proceedings of the National Academy of Science of the United States of America (PNAS).

Related Links:

Lund University



Channels

Genomics/Proteomics

view channel
Image: Typical antibodies (left) unfold in the harsh environment of the cell. Camelid antibodies (right) are smaller and more stable (Photo courtesy of the Washington University School of Medicine).

Double Targeting Approach Increases Potential for Cancer Treatment with Oncolytic Viruses

Cancer researchers have used a double targeting approach to direct oncolytic viruses specifically to tumor cells where they reproduce until the cancer cells burst, releasing more viruses to infect and... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.